Last reviewed · How we verify
NCT07362745
Single-Cell and Spatial Transcriptomics Analysis of Steatotic Donor Liver Susceptibility to Post-Transplant Injury
trial in Fatty Liver in 300 participants. Completed in 1 January 2026.
1 January 2026
Quick facts
| Lead sponsor | Xijing Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 1 January 2015 |
| Primary completion | 1 January 2026 |
| Estimated completion | 1 January 2026 |
| Sites | 1 location across China |
Conditions studied
- Fatty Liver — all drugs for Fatty Liver →
- Liver Transplant; Complications — all drugs for Liver Transplant; Complications →
- Ischaemia Reperfusion Injury of Liver — all drugs for Ischaemia Reperfusion Injury of Liver →
- End Stage Liver Disease — all drugs for End Stage Liver Disease →
Sponsor
Xijing Hospital
Who can join
Adults 18 to 80, any sex, with Fatty Liver or Liver Transplant; Complications. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to understand why liver transplants from donors with fatty liver disease (steatotic donor livers) are more vulnerable to post-transplant injury, analyzing historical clinical data and collected tissue samples using advanced genetic techniques. The main questions it aims to answer are: * Which specific cell types and their spatial interactions contribute to increased post-transplant injury susceptibility in steatotic donor livers? * What are the key molecular differences in gene expression between steatotic and normal donor livers following transplantation? Researchers will compare 300 historical liver transplant cases from 2015-2025, including 50 cases with archived tissue samples available for molecular analysis, and 250 cases with clinical data only. Donor liver steatosis was assessed by histopathology when tissue was available, or by donor clinical data when tissue was not available. The two groups (steatotic donor liver recipients vs. normal donor liver recipients) will be matched based on donor age, ischemia time, recipient scores, and other key clinical parameters to control for potential confounding variables. This is a retrospective analysis of existing data and archived biospecimens; no prospective participant enrollment or additional sample collection will occur.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07362745
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Fatty Liver
Currently open trials in the same condition.
- NCT07242222 — Erdosteine in the Treatment of Nonalcoholic Fatty Liver Disease · Phase 1, PHASE2 · recruiting
- NCT07238985 — Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease · Phase 1, PHASE2 · recruiting
- NCT06661655 — Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients · NA · recruiting
- NCT06989723 — Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes · Phase 4 · recruiting
- NCT06203548 — Monitoring Changes in Hepatic Steatosis Using Continuous Controlled Attenuation Parameter · NA · recruiting
Other Xijing Hospital trials
Trials by the same sponsor.
- NCT07532096 — Extended Sentinel Lymph Node Biopsy With Methylene Blue Single Tracer Post-Neoadjuvant Therapy for Node-Positive Breast · NA · not yet recruiting
- NCT07519018 — TIS for Drug Resistant TLE · NA · not yet recruiting
- NCT07518992 — Correlation Between Preoperative Sleep and Postoperative Brain and Renal Dysfunction · not yet recruiting
- NCT07466303 — Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07474142 — A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve P · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07362745 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xijing Hospital
- Last refreshed: 6 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07362745.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing